Mark A Glickman Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Mark A Glickman.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Mark A Glickman. Mark A Glickman is a SVP, Sales & Marketing in OSCIENT PHARMACEUTICALS CORP ($GENE) and a Chief Commercial Officer in POZEN INC /NC ($POZN) and a Chief Commercial Officer in Esperion Therapeutics, Inc. ($ESPR) and a Chief Commercial Officer in Aralez Pharmaceuticals Inc. ($ARLZ).
Address: 23 ORCHARD ROAD SUITE 101 SKILLMAN 08558 NJ
Companies in which Mark A Glickman is an Insider
Esperion Therapeutics, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Mark A Glickman: Chief Commercial Officer
Holdings: 25,925 shares
Current Value: $457,836
Latest Transaction: Jan 03 2020
$ESPR Market Capitalization: $454.22M
$ESPR Previous Close: $17.66
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Old API Wind-down Ltd.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Mark A Glickman: Chief Commercial Officer
Holdings: 250,188 shares
Current Value: $1,048,288
Latest Transaction: Mar 21 2018
$ARLZ Market Capitalization: $270.87M
$ARLZ Previous Close: $4.19
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
OSCIENT PHARMACEUTICALS CORP
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Mark A Glickman: SVP, Sales & Marketing
Holdings: 36,157 shares
Current Value: $40,857
Latest Transaction: Jul 30 2008
$GENE Market Capitalization: $13.04M
$GENE Previous Close: $1.13
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
POZEN INC /NC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Mark A Glickman: Chief Commercial Officer
Holdings: 29,137 shares
Latest Transaction: Jun 24 2015
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Mark A Glickman
Sentiment: All, ESPR, ARLZ, GENE, POZN
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 03 2020 | ESPR | Esperion Therapeut ... | Glickman Mark A | Chief Commercial Of ... | Option Exercise | A | 61.34 | 26,625 | 1,633,178 | 26,625 | |
| Jan 03 2020 | ESPR | Esperion Therapeut ... | Glickman Mark A | Chief Commercial Of ... | Grant | A | 0.00 | 5,925 | 0 | 25,925 | 20 K to 25.9 K (+29.63 %) |
| Mar 21 2018 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Sell | S | 1.70 | 5,725 | 9,733 | 250,188 | 255.9 K to 250.2 K (-2.24 %) |
| May 12 2017 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Option Exercise | A | 1.56 | 92,621 | 144,489 | 92,621 | |
| May 12 2017 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Grant | A | 0.00 | 80,163 | 0 | 255,913 | 175.8 K to 255.9 K (+45.61 %) |
| Jun 24 2016 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Payment of Exercise | F | 3.34 | 10,803 | 36,082 | 175,750 | 186.6 K to 175.8 K (-5.79 %) |
| May 18 2016 | ARLZ | Aralez Pharmaceuti ... | Glickman Mark A | Chief Commercial Of ... | Buy | P | 3.68 | 25,000 | 92,050 | 186,553 | 161.6 K to 186.6 K (+15.47 %) |